Company Legal Name
Latest Valuation
Founded Year
Headquarters
Eikon Therapeutics operates a drug discovery platform that combines live-cell protein tracking technology with advanced data science to develop treatments for serious diseases. Founded in 2019 and headquartered in Hayward, California, the company differentiates itself through its proprietary approach to observing protein behavior in living cells, providing unprecedented insights into disease mechanisms. This innovative methodology enables more precise identification of therapeutic targets and drug candidates compared to traditional discovery methods. The company focuses on leveraging its unique technological capabilities to advance a pipeline of potential treatments addressing significant unmet medical needs in various therapeutic areas.
Availability of information and platform features may vary by region and applicable requirements.
Eligibility and access may depend on user location, verification status, and applicable legal or regulatory requirements.
Additional platform details may be available after account creation, where applicable.
Identity, compliance, and other review steps may be required before access to certain materials or features.
Platform details, if applicable, should be reviewed in account materials before making any decision.
Any economic terms, if applicable, should be reviewed carefully in the relevant materials.
Private market interests may be illiquid, restricted, or difficult to transfer. Users should not assume that any secondary market will be available.
Valuations may reflect past financing rounds or other available information and may not represent a price at which any person can transact.
Company and sector risks may vary by business model, technology development, competition, regulation, and market conditions.
Operational, documentation, custody, or verification processes may involve limitations, delays, or dependencies.
Regulatory, tax, and legal requirements may change and may affect information availability, platform features, or user eligibility.
